Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C

doi:10.3748/wjg.v21.i35.10215

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 35

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7404)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

340

WORD

257

HTML

3544

Figures (1-1)

193

Tables (1-4)

176

Sum=4510

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1101

Download

1793

Sum=2894

Sep 21, 2015 (publication date) through Jul 17, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Sep 21, 2015; 21(35): 10215-10223
Published online Sep 21, 2015. doi: 10.3748/wjg.v21.i35.10215

Table 3 Characteristics of genotype1 patients studied

	All	SVRs	Relapsers and NVRs	P value
Number of patients	57	17	40
Gender (female/male)	34/23	7/10	25/15	NS
Age (yr)	59 (50-66)	51 (41-58)	62 (54-67)	0.0016
Fibrosis stage (F0-F2 /F3,4)¹	25/17	12/0	13/17	< 0.0001
Inflammatory grade (A0,1/A2,3)¹	16/26	6/6	10/20	NS
Platelet count (× 10⁴/μL)	14.0 (10.7-18.3)	15.4 (13.0-19.5)	13.2 (9.4-17.4)	NS
Prothrombin time (%)	99 (91-111)	102 (91-110)	98 (92-112)	NS
Albumin (g/dL)	4.2 (4.0-4.5)	4.4 (4.2-4.6)	4.2 (4.0-4.4)	0.0496
Total bilirubin (mg/dL)	0.8 (0.6-1.0)	0.8 (0.5-1.1)	0.8 (0.6-1.0)	NS
AST (IU/L)	47 (32-71)	38 (28-63)	48 (35-77)	NS
ALT (IU/L)	50 (35-90)	50 (30-92)	52 (36-91)	NS
γ-GTP (IU/L)	33 (22-51)	37 (15-66)	30 (23-50)	NS
ALP (U/L)	267 (212-379)	246 (187-262)	314 (215-416)	0.0053
Hyaluronic acid (ng/mL)	95 (46-173)	51 (21-98)	114 (68-180)	0.0076
HCV RNA (logIU/mL)	6.4 (5.8-7.0)	6.0 (5.2-7.1)	6.4 (6.1-6.9)	NS
APRI	0.91 (0.56-1.69)	0.80 (0.45-1.09)	1.05 (0.63-1.73)	NS
FIB-4	2.69 (1.64-4.46)	1.66 (1.26-2.53)	3.34 (2.23-4.63)	0.0014
Vs (m/s); Before treatment	1.44 (1.17-1.75)	1.28 (1.04-1.40)	1.56 (1.20-1.83)	0.0142

¹Fibrosis stage and Inflammatory grade performed by a χ² testing. Comparison between SVRs and non-SVRs (Relapser/NVRs). Data are shown as median (interquartile range). AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γ-GTP: γ-glutamyltranspeptidase; ALP: Alkaline Phosphatase; APRI: Aminotransferase-to-platelet ratio index; FIB-4: Fibrosis-4; NVR: Non-virological responders; SVR: Sustained virological responder.

Citation: Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Shibata A, Asada W, Kawabe N, Hashimoto S, Murao M, Nakano T, Shimazaki H, Kan T, Nakaoka K, Takagawa Y, Ohki M, Kurashita T, Takamura T, Yoshioka K. Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. World J Gastroenterol 2015; 21(35): 10215-10223
URL: https://www.wjgnet.com/1007-9327/full/v21/i35/10215.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i35.10215